pharma news today obesity drugs glp-1 today Agonists Weight Loss Market Report, 2025-2030 GLP-1 drugs changed the obesity

These medicines, now widely used in the UK for obesity, diabetes, and metabolic conditions, can support significant weight loss and improved blood sugar control

And for those using BPC-157 or TB-500 for recovery alongside their GLP-1 therapy, the BPC-157 and TB-500 stacking guide along with the BPC-157 versus TB-500 comparison provides detailed guidance on combining these compounds safely

Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below

They target the body and mind simultaneously, helping to reduce a primary cause of weight gain: a strong appetite that leads to overeating

However, oral bioavailability is only about 1%, meaning you need a much higher absolute dose to achieve comparable blood levels to the injectable form

Diabetologia 63 , 473485 (2020)